Table 1.
Patient number | Sex | Age (years) | Duration of disease (months)* | Platelet counts (×109/L) | Response to first-line therapies | |
---|---|---|---|---|---|---|
Before treatment | After treatment | |||||
1 | F | 56 | 6 | 8 | 6 | NR |
2 | F | 28 | 8 | 11 | 56 | PR |
3 | M | 38 | 2 | 12 | 26 | NR |
4 | F | 63 | 1 | 18 | 84 | PR |
5 | F | 47 | 12 | 9 | 45 | PR |
6 | F | 67 | 5 | 2 | 169 | CR |
7 | M | 46 | 20 | 8 | 227 | CR |
8 | F | 52 | 1 | 13 | 175 | CR |
9 | M | 19 | 18 | 7 | 239 | CR |
10 | F | 34 | 14 | 3 | 18 | NR |
11 | M | 41 | 7 | 17 | 157 | CR |
12 | F | 68 | 21 | 6 | 193 | CR |
13 | F | 43 | 2 | 5 | 296 | CR |
14 | F | 36 | 4 | 12 | 137 | CR |
15 | F | 50 | 14 | 14 | 15 | NR |
16 | F | 79 | 4 | 4 | 46 | PR |
17 | M | 35 | 1 | 1 | 6 | NR |
18 | F | 38 | 5 | 8 | 186 | CR |
19 | F | 59 | 9 | 15 | 24 | NR |
20 | F | 67 | 32 | 22 | 47 | PR |
21 | M | 33 | 1 | 3 | 134 | CR |
22 | F | 73 | 15 | 18 | 214 | CR |
23 | M | 24 | 1 | 7 | 151 | CR |
24 | F | 24 | 1 | 6 | 86 | PR |
25 | F | 50 | 4 | 8 | 65 | PR |
26 | M | 50 | 20 | 12 | 26 | NR |
27 | F | 30 | 12 | 8 | 38 | PR |
28 | F | 28 | 8 | 16 | 64 | PR |
29 | M | 46 | 32 | 20 | 84 | PR |
30 | F | 54 | 16 | 13 | 23 | NR |
31 | M | 62 | 2 | 7 | 141 | CR |
32 | F | 49 | 6 | 11 | 137 | CR |
33 | F | 35 | 10 | 3 | 192 | CR |
34 | F | 37 | 1 | 12 | 179 | CR |
35 | F | 51 | 4 | 17 | 231 | CR |
Median | — | 46 | 6 | 9 | 137 | — |
(Min.–max.) | — | (19–79) | (1–32) | (1–22) | (6–296) | — |
*Approximately estimated according to initial manifestation of bleeding symptoms and/or platelet count <100 (×109/L).